Cellular Therapies Program

For Leukemia

• Trial 22-679: A phase 2, open-label, multicenter, basket study evaluating the safety and efficacy of brexucabtagene autoleucel in adults with rare B-cell malignancies (Zuma 25)
  Principal Investigator: Shayna Sarosiek, MD
• Trial 20-562: A phase 1, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL)
  Principal Investigator: Daniel DeAngelo, MD, PhD
• Trial 18-608: A phase 1/2a, open-label, dose-escalation, dose-expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR0191 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and r/r B-cell acute lymphoblastic leukemia (B-ALL)
  Principal Investigator: Caron Jacobson, MD, MMSc
• Trial 18-233: A phase 1, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with relapsed/refractory acute myeloid leukemia, and patients with newly diagnosed high-risk acute myeloid leukemia
  Principal Investigator: Daniel DeAngelo, MD, PhD

For more information, contact our Adult Leukemia Program.

For Lymphoma

• Trial 22-679: A phase 2, open-label, multicenter, basket study evaluating the safety and efficacy of brexucabtagene autoleucel in adults with rare B-cell malignancies (Zuma 25)
  Principal Investigator: Shayna Sarosiek, MD
• Trial 22-271: A phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory follicular lymphoma
  Principal Investigator: Caron Jacobson, MD, MMSc
• Trial 21-124: A multicenter single arm phase 2 study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in patients with relapsed and/or refractory diffuse large B-cell lymphoma
  Principal Investigator: Caron Jacobson, MD, MMSc
  
• Trial 20-274: A phase 1 study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory primary and secondary central nervous system (CNS) lymphoma
  Principal Investigator: Caron Jacobson, MD, MMSc
  
• Trial 18-608: A phase 1/2a, open-label, dose-escalation, dose-expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR0191 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and r/r B-cell acute lymphoblastic leukemia (B-ALL)
  Principal Investigator: Caron Jacobson, MD, MMSc

For more information, contact our Adult Lymphoma Program.

For Multiple Myeloma

• Trial 22-546: CAR-PRISM (precision intervention smoldering myeloma): A chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA in high-risk smoldering myeloma
  Principal Investigator: Irene Ghobrial, MD
• Trial 22-533: A phase 2 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (ARC112A, iMMagine-1)
  Principal Investigator: Adam Sperling, MD, PhD
• Trial 22-311: A phase 2 study of PHE885, B-cell maturation antigen (BCMA)-directed CAR-T cells in adult participants with relapsed and refractory multiple myeloma
  Principal Investigator: Adam Sperling, MD, PhD
• Trial 21-019: A phase 1, multicenter, open label study of CC-95266 In patients with relapsed and/or refractory multiple myeloma
  Principal Investigator: Omar Nadeem, MD
• Trial 20-120: A phase 1 study of autologous memory-like natural killer (NK) cell immunotherapy in combination with KP1237 and low-dose IL-2 as early post-autologous transplant consolidation in minimal residual disease positive, newly diagnosed multiple myeloma patients
  Principal Investigator: Giada Bianchi, MD
• Trial 19-785: A phase 1, open label, study of B-cell maturation antigen (BCMA)-directed CAR-T cells in adult patients with relapsed and/or refractory multiple myeloma
  Principal Investigator: Adam Sperling, MD, PhD
• Trial 19-453: Open label, multi-center, phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
  Principal Investigator: Jacob Laubach, MD, MPP
• Trial 18-604: A phase 2, multicohort, open-label, multicenter study to evaluate the efficacy and safety of bb2121 in patients with relapsed and refractory multiple myeloma and in patients with clinical high-risk multiple myeloma (KarMMa-2)
  Principal Investigator: Adam Sperling, MD, PhD

For more information, contact our Multiple Myeloma Program.

For Solid Tumors

• Trial 22-395: A phase 1 multicenter study evaluating the safety and tolerability of GCC19CART in patients with relapsed or refractory metastatic colorectal cancer (CARAPIA-1)
  Principal Investigator: Benjamin Schlechter, MD
• Trial 21-062: A phase 1/2 trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2)
  Principal Investigator: Benjamin Schlecter, MD
• Trial 19-505: A phase 1 trial of CTLA-4 inhibition in combination with memory-like natural killer (NK) cell immune cell therapy in advanced head and neck cancer
  Principal Investigator: Glenn Hanna, MD

For more information, contact the relevant solid tumor treatment center.

Cell Manipulation Core Facility

For some cellular therapy products – especially in early phase clinical trials – our on-site Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) performs the primary cell manufacturing of genetically engineered products. For other cellular therapy products, cells are primarily manufactured at an outside commercial facility and the CMCF oversees the process of collecting the cells, shipment to the offsite commercial facility, return of the processed cells, and release for patient treatment.